SEC Filings
State Street Reports 4.7% Rigel Stake While Drug Sales Rise And Quarterly Profit Falls
The passive holding covered 879,862 shares as of September 30; Rigel still expects positive full-year net income.
Rigel Pharmaceuticals (RIGL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The passive holding covered 879,862 shares as of September 30; Rigel still expects positive full-year net income.
SEC Filings
Veppanu brought in $6.6 million in initial sales, while Rigel narrowed its annual revenue outlook, which excludes the breast-cancer drug.
Earnings
The cancer drug's first sales covered about six weeks, and the CFO said guidance on it will wait until after the first of the year.